

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.

Spinal Analgesic Interaction Between Non-Steroidal Anti-
Inflammatory Drugs and *N*-Methyl-D-Aspartate Receptor
Systems

A thesis presented in partial fulfilment
of the requirements for the degree of

Doctor of Philosophy in Veterinary Science

Institute of Veterinary, Animal and Biomedical Sciences
Massey University
Palmerston North, New Zealand

Ignacio Lizarraga-Madrigal
2006

To Fernanda

Abstract

Activation of spinal *N*-methyl-D-aspartate (NMDA) receptors stimulates cyclooxygenase and nitric oxide pathways. Compounds that block the activity of these NMDA receptor systems reduce pain hypersensitivity. However, their usefulness is limited by the side effects they produce. One way of reducing side effects is by combining drugs that produce the same overt effect by different mechanisms, which hopefully increase the net effect. In these series of studies, drugs that interact with NMDA receptor systems and their combinations were screened *in vitro* to identify spinal antinociceptive synergistic combinations that could be assessed *in vivo*. Based on developmental changes in thresholds, conduction velocities and blocking actions of the local anaesthetic lignocaine in neonatal rat L4/L5 dorsal root potentials, it was decided to use spinal cord *in vitro* preparation from 5- to 7-day-old rat pups. In single drug studies, the NMDA receptor channel blocker ketamine (1-50 μM) and the non-steroidal anti-inflammatory drug (NSAID) ketoprofen (200-600 μM), but not the NSAID salicylate (1000 μM) and the nitric oxide synthase inhibitor *N*^ω-nitro-L-arginine methyl ester (L-NAME; 1-100 μM), reduced spinal NMDA receptor-mediated transmission. Ketamine also depressed non-NMDA receptor-mediated transmission. Using isobolographic and composite additive line analyses, fixed-ratio combinations of ketamine and ketoprofen, ketamine and L-NAME, and ketoprofen and L-NAME synergistically depressed NMDA receptor-mediated transmission. The two former combinations had a subadditive effect on non-NMDA receptor-mediated transmission, and the latter had no significant effect. These studies identified that all combinations synergistically reduced both nociceptive transmission and potential side effects. In free-moving sheep implanted with indwelling cervical intrathecal catheters, 100 μl subdural administration of ketamine (25-400 μM) and ketoprofen (200-3200 μM) alone and in a fixed-ratio combination (873.95-3350.78 μM , 0.045:0.955) did not raise nociceptive thresholds as assessed by mechanical stimulation of one foreleg. Subdural administration of NMDA (2 mM) decreased mechanical nociceptive thresholds, and this was prevented by the highest concentrations of ketamine and ketoprofen alone and in combination. These findings demonstrated that NMDA receptor channel blockers and NSAIDs alone or in combination had no direct hypoalgesic effects when given onto the spinal cord of sheep, but they prevented NMDA-induced pain hypersensitivity. Simultaneous blockade of NMDA receptor systems could have important clinical implications.

Acknowledgements

I am extremely thankful to Paul Chambers and Craig Johnson for supervising this project. I appreciate all your academic and intellectual support, but mostly your friendship and generosity of time.

I could not have carried out this project without sponsorship of the National Autonomous University of Mexico, in particular the DGAPA scholarship I was granted and the support of the Faculty of Veterinary Medicine during my leave.

Special thanks to the Neuroscience Group in IVABS, in particular to Sheryl Mitchinson for her skilled assistance during sheep anaesthesia. Special thanks also go to Debbie Chesterfield, Judith Stanton and Louise Beazley from the Small Animal Production Unit for providing the rats for this project, and to Robin Whitson and Graeme King for looking after the sheep while housed in the Veterinary Teaching Hospital.

Thanks to Wendi Roe, Stuart Hunter, Mark Collett, and Alastair Johnstone for their expert advice in gross pathology and histopathology, to Nicolas Lopez-Villalobos for his advice on statistical analyses, to Aaron Hicks for processing the rat dorsal roots for histological examination, and to Allain Scott for her support with all postgraduate administrative requirements.

During this time in New Zealand I met extraordinary people who helped me in many different ways. Very special thanks to Alejandra, Victor, Natalia, Alfredo, Federico, Klelia, and the Whelan family. Also thanks to old friends, Kathy and Mike, Oscar and Sara, Sue and Godfrey, David and Diana, Patricia and Jose, and Sylvia.

I am grateful to my parents, Ignacio and Silvia, who have always been there for me and for being such great role models. Also to my family and friends in Mexico that kept me cheerful during this time.

Finally, I am most grateful to Fernanda. Thanks for all your help on every single part of this project, but mainly for being the wonderful person you are and sharing this journey with me. You mean all to me and I wish I could put in words how much I love you...

Table of contents

Abstract.....	V
Acknowledgements.....	VII
Table of contents.....	IX
List of tables.....	XII
List of figures.....	XV
Abbreviations.....	XXIII
1. Introduction and thesis outline.....	1
1.1 Introduction.....	1
1.1.1 The research problem.....	2
1.2 Thesis outline.....	3
1.3 References.....	4
2. Spinal processing of pain: a review on NMDA receptor-mediated activation of arachidonic acid and nitric oxide signalling pathways.....	7
2.1 Spinal NMDA receptors.....	7
2.1.1 Regulation of spinal NMDA receptors.....	7
2.1.2 NMDA receptors and the spinal nociceptive process.....	11
2.2 NMDA receptors and the arachidonic acid pathway.....	13
2.2.1 Phospholipases A ₂ and the spinal nociceptive process.....	14
2.2.2 Cyclo-oxygenases and the spinal nociceptive process.....	15
2.2.3 Prostaglandins and the spinal nociceptive process.....	22
2.2.4 Prostaglandin receptors and the spinal nociceptive process.....	24
2.2.5 Protein kinases A and C and the spinal nociceptive process.....	28
2.3 NMDA receptors and the nitric oxide pathway.....	29
2.3.1 Nitric oxide synthases and the spinal nociceptive process.....	30
2.3.2 Nitric oxide and the spinal nociceptive process.....	33
2.3.3 Guanylate cyclases and the spinal nociceptive process.....	34
2.3.4 cGMP-dependent protein kinases and the spinal nociceptive process.....	36
2.3.5 Poly(ADP-ribose) synthase and the spinal nociceptive process.....	37
2.4 Spinal interactions between arachidonic acid and nitric oxide pathways.....	37
2.4.1 Effects of cyclo-oxygenase pathway modulation on nitric oxide synthesis.....	37
2.4.2 Effects of nitric oxide pathway modulation on prostaglandin synthesis.....	38

2.4.3 Nitric oxide pathway and spinal cyclo-oxygenase inhibition-mediated analgesia.....	38
2.5 References.....	39
3. Developmental changes in threshold, conduction velocity and depressive action of flignocaine on dorsal root potentials from neonatal rats are associated with maturation of myelination.....	55
3.1 Abstract.....	55
3.2 Introduction.....	55
3.3 Material and methods.....	57
3.4 Results.....	62
3.5 Discussion.....	67
3.6 References.....	75
4. Depression of NMDA receptor-mediated segmental transmission by ketamine and ketoprofen, but not L-NAME, on the <i>in vitro</i> neonatal rat spinal cord preparation.....	79
4.1 Abstract.....	79
4.2 Introduction.....	79
4.3 Material and methods.....	80
4.4 Results.....	84
4.5 Discussion.....	91
4.6 References.....	97
5. Synergistic depression of nociceptive segmental reflexes by ketamine and ketoprofen on the <i>in vitro</i> neonatal rat spinal cord preparation.....	101
5.1 Abstract.....	101
5.2 Introduction.....	101
5.3 Material and methods.....	103
5.4 Results.....	105
5.5 Discussion.....	108
5.6 References.....	111
6. Ketamine and L-NAME synergistically depress NMDA receptor-mediated transmission on the <i>in vitro</i> neonatal rat spinal cord preparation.....	115
6.1 Abstract.....	115
6.2 Introduction.....	115
6.3 Material and methods.....	117
6.4 Results.....	118

6.5 Discussion.....	121
6.6 References.....	124
7. Synergistic depression of C-fibre-mediated synaptic transmission by ketoprofen and L-NAME on the <i>in vitro</i> neonatal rat spinal cord preparation.....	127
7.1 Abstract.....	127
7.2 Introduction.....	127
7.3 Material and methods.....	128
7.4 Results.....	130
7.5 Discussion.....	133
7.6 References.....	135
8. Reduction of NMDA-induced mechanical hypersensitivity by intrathecal administration of ketoprofen and ketamine in sheep.....	139
8.1 Abstract.....	139
8.2 Introduction.....	139
8.3 Material and methods.....	140
8.4 Results.....	148
8.5 Discussion.....	157
8.6 References.....	162
9. General discussion and conclusions.....	167
9.1 <i>In vitro</i> sciatic nerve-dorsal root preparation.....	167
9.2 <i>In vitro</i> spinal cord preparation.....	169
9.2.1 Development of spinal NMDA receptor systems.....	169
9.2.2 Single drug studies.....	170
9.2.3 Drug combination studies.....	171
9.3 Intrathecal drug administration in sheep.....	173
9.4 References.....	174

List of tables

Table 2.1 Expression and anatomical distribution of mRNAs encoding for the different NMDA receptor splice variants in the lumbar spinal cord of the rat.....	12
Table 2.2 Constitutive expression of cyclo-oxygenase isozymes in the spinal cord.....	17
Table 2.3 Effects of spinal administration of cyclo-oxygenase inhibitors on different algometric tests.....	18
Table 2.4 Constitutive expression of prostaglandin and thromboxane synthases in the spinal cord.....	22
Table 2.5 Classification and signal transduction pathways of prostanoid receptors.....	25
Table 2.6 Expression of prostanoid receptors in the spinal cord and dorsal root ganglia neurones.....	26
Table 2.7 Constitutive expression of nitric oxide synthase isozymes in the spinal cord.....	31
Table 3.1 Correlation and (<i>P</i>) values for threshold (τ) and conduction velocity (<i>cv</i>) of, and effect of lignocaine (<i>lingo</i>) and capsaicin (<i>caps</i>) on A- (A) and C-fibre waveforms (C), and for myelination (<i>myelin</i>).....	69
Table 5.1 IC_{40} values with 95% confidence intervals (CI) for the depressive effect of ketamine (1-50 μ M) and ketoprofen (200-600 μ M) on the three evoked spinal segmental responses.....	105
Table 5.2 Theoretical and experimental IC_{40} values with 95% confidence intervals (CI) for combinations of ketoprofen and ketamine in a fixed drug proportion on the three evoked spinal segmental responses.....	107
Table 6.1 Theoretical and experimental IC_{40} values with 95% confidence intervals (CI) for combinations of ketamine and L-NAME in a fixed drug proportion on the three evoked spinal segmental responses.....	119
Table 7.1 IC_{40} values with 95% confidence intervals (CI) for the depressive effect of ketoprofen (200-600 μ M) and L-NAME (1-100 μ M) on the three evoked spinal	

segmental responses.....130

Table 7.2 Theoretical and experimental IC_{40} values with 95% confidence intervals (CI) for combinations of ketoprofen and L-NAME in a fixed drug proportion on the three evoked spinal segmental responses.....131

Table 8.1 Distribution of sheep used in the experiments.....146

Table 8.2 Summary of cervical intrathecal catheterisation and effects of xylazine injected through the intrathecal catheter on nociceptive mechanical thresholds in healthy sheep.....149

List of figures

Figure 1.1 Schematic representation of neurotransmission of pain signals from the periphery to higher centres of the brain and back to the spinal cord.....	3
Figure 2.1 Schematic representation of pain neurotransmission in the spinal cord.....	8
Figure 3.1 Schematic representation of the experimental setting for the sciatic nerve-dorsal root preparation.....	58
Figure 3.2 High power images of transverse sections of L5 dorsal root from a 12-day-old rat.....	61
Figure 3.3 Developmental changes in L4 or L5 dorsal root A- (a) and C-fibre thresholds (b) after electrical stimulation of the sciatic nerve of 0- to 12-day-old rats.....	63
Figure 3.4 Action potential recordings from a L4/L5 dorsal root-sciatic nerve preparation from a 6-day-old rat.....	64
Figure 3.5 Developmental changes in conduction velocity of A- (a) and C-fibre waveforms (b) from L4 or L5 DRCAPs of 0- to 12-day-old rats.....	65
Figure 3.6 Developmental changes in the depressive action of lignocaine on A- and C-fibre waveforms from L4 or L5 DRCAPs of 0- to 12-day-old rats.....	66
Figure 3.7 DRCAPs from 11-day-old rat preparations. (a) Recordings in this column show the selective depressive action of capsaicin (2 μ M) on the C-fibre waveform. (b) Recordings in this column show the lack of effect of ethanol (0.192%).....	67
Figure 3.8 Effect of capsaicin and ethanol on A- and C-fibre waveforms from L4 or L5 DRCAPs of 0- to 12-day-old rats.....	68
Figure 3.9 Developmental changes in myelination of L4 or L5 dorsal roots in 0- to 12-day-old rats.....	68
Figure 4.1 Schematic representation of the experimental setting for the <i>in vitro</i> neonatal rat spinal cord preparation.....	82

Figure 4.2 Time course showing the effect of artificial cerebrospinal fluid (aCSF) on the different components of the synaptic response (mean \pm s.e.m.).....84

Figure 4.3 (a-c) Effects of ketamine (50 μ M) on the synaptic responses. Ketamine depressed the MSR (a), the low intensity epsp (b), and the high intensity epsp (c). Recovery is shown in the right panels after 90 min of ketamine-free medium. (d) Time course showing the depressant actions of ketamine on the different components of the synaptic response (mean \pm s.e.m). At the time that reached equilibrium (30 min after infusion), 50 μ M ketamine depressed the MSR by 76.03 ± 1.39 %, the low intensity epsp by 63.70 ± 1.99 %, and the high intensity epsp by 43.9 ± 8.35 %..... 85

Figure 4.4 (a) Time course showing the depressant actions of ketamine (1-50 μ M) and the lack of activity of naloxone (1 μ M) to reverse ketamine's depressant effects (mean \pm s.e.m). (b) Concentration-effect plot showing the effect of ketamine. IC_{50} values (with 95% CI) were 10.8 (5.97 to 19.54) μ M for the MSR, 8.29 (4.53 to 15.17) μ M for the low intensity epsp, and 5.35 (3.05 to 9.40) μ M for the high intensity epsp.... 86

Figure 4.5 (a) Time course showing the lack of depressive effect of L-NAME (1-100 μ M) on the different components of the synaptic response (mean \pm s.e.m). (b) Concentration-effect plot showing the lack of effect of L-NAME.....87

Figure 4.6 Time course showing the lack of depressive effect of salicylic acid (1000 μ M) on the different components of the synaptic response (mean \pm s.e.m)..... 88

Figure 4.7 (a-c) Effects of ketoprofen (600 μ M) on the synaptic responses. Ketoprofen depressed the low intensity epsp (b) and the high intensity epsp (c), but had no effect on the MSR (a). Recovery is shown in the right panels after 60 min of ketoprofen-free medium. (d) Time course showing the actions of ketoprofen on the different components of the synaptic response (mean \pm s.e.m). At the time that reached equilibrium (35 min after infusion), 600 μ M ketoprofen depressed the low intensity epsp by 35.00 ± 3.69 % and the high intensity epsp by 51.08 ± 9.38 %, but had a minor depressive effect on the MSR (5.54 ± 2.17 %).....89

Figure 4.8 (a) Time course showing the depressant actions of ketoprofen (200-600 μ M) on the synaptic responses (mean \pm s.e.m). (b) Concentration-effect plot showing the effect of ketoprofen. IC_{50} values (with 95% CI) were 354.2 (217.5 to 576.8) μ M for the low intensity epsp, and 302.7 (174.0 to 526.7) μ M for the high intensity epsp..... 90

Figure 4.9 Time courses showing the lack of depressive effect of anandamide (0.1-1 μM) on individual recordings for (a) the MSR, (b) the low intensity epsp, and (c) the high intensity epsp.....91

Figure 5.1 (a) Percent maximal possible effect (MPE%) of ketoprofen alone (A), ketamine alone (B), ketoprofen and ketamine in a theoretical additive fixed ratio proportion (0.955 : 0.045) in which the quantities of the constituents are in proportion to their respective IC_{40} values (C), and the actual combination of ketoprofen and ketamine having the same proportion (D) for the low intensity epsp. The horizontal dashed line represents the effect level 40% MPE. (b) Isobologram for low intensity epsp at the effect level 40% MPE for the combinations ketoprofen and ketamine in a fixed ratio proportion as indicated above. The solid line is the line of additivity and contains point A representing the calculated additivity quantities for this proportional combination. Point C is the combination point determined experimentally with this same proportional mix. Coordinates of point A are [(264.32 (223.72 - 327.80) μM , 12.43 (10.52 - 15.41) μM] and those of point C [(93.23 (77.48 - 108.27) μM , 4.38 (3.64 - 5.09) μM].....106

Figure 5.2 (a) Percent maximal possible effect (MPE%) of ketoprofen alone (A), ketamine alone (B), ketoprofen and ketamine in a theoretical additive fixed ratio proportion (0.952 : 0.048) in which the quantities of the constituents are in proportion to their respective IC_{40} values (C), and the actual combination of ketoprofen and ketamine having the same proportion (D) for the high intensity epsp. The horizontal dashed line represents the effect level 40% MPE. (b) Isobologram for low high epsp at the effect level 40% MPE for the combinations ketoprofen and ketamine in a fixed ratio proportion as indicated above. The solid line is the line of additivity and contains point A representing the calculated additivity quantities for this proportional combination. Point C is the combination point determined experimentally with this same proportional mix. Coordinates of point A are [184.28 (113.10 - 234.88) μM , 9.31 (5.72 - 11.86) μM] and those of point C [61.61 (33.13 - 86.96) μM , 3.11 (1.68 - 4.40) μM].....106

Figure 5.3 (a) Percent maximal possible effect (MPE%) of ketoprofen alone (A), ketamine alone (B), and the actual combination of ketoprofen and ketamine in a fixed ratio proportion (0.955 : 0.045) in which the quantities of ketamine are in 0.5 fractions to its respective IC_{40} value (D) for the MSR. The horizontal dashed line represents the effect level 40% MPE. (b) Isobologram for low intensity epsp at the effect level 40% MPE for the combinations ketoprofen and ketamine in a fixed ratio proportion as indicated above. The dashed line is the line of additivity and

contains point A representing the calculated additivity quantities for this proportional combination. Point C is the combination point determined experimentally with this same proportional mix. Coordinates of point A are [(164.49 (126.03 - 212.18) μM , 7.75 (9.94 - 10.00) μM] and those of point C (5164.32 μM , 243.35 μM ; CI were too wide and hence not included).....108

Figure 6.1 (a) Percent maximal possible effect (MPE%) of L-NAME alone (A), ketamine alone (B) and the actual combination of ketamine and L-NAME in a fixed ratio proportion (0.8805 : 0.1195) in which the quantities of ketamine are in 0.5 fractions to its respective IC_{40} value (D) on the MSR. The horizontal dashed line represents the effect level 40% MPE. (b) Isobologram for the MSR at the effect level 40% MPE for the combinations ketamine and L-NAME in a fixed ratio proportion as indicated above. The dashed line is the line of additivity and contains point A representing the calculated additivity quantities for this proportional combination. Point C is the combination point determined experimentally with this same proportional mix. Coordinates of point A are [7.75 (5.94 - 10.00) μM , 1.05 (0.81 - 1.36) μM] and those of point C [14.46 (11.55 - 19.05) μM , 1.96 (1.57 - 2.59) μM].....120

Figure 6.2 (a) Percent maximal possible effect (MPE%) of L-NAME alone (A), ketamine alone (B) and the actual combination of ketamine and L-NAME in a fixed ratio proportion (0.8805 : 0.1195) in which the quantities of ketamine are in 0.5 fractions to its respective IC_{40} value (D) on the low intensity epsp. The horizontal dashed line represents the effect level 40% MPE. (b) Isobologram for the low intensity epsp at the effect level 40% MPE for the combinations ketamine and L-NAME in a fixed ratio proportion as indicated above. The dashed line is the line of additivity and contains point A representing the calculated additivity quantities for this proportional combination. Point C is the combination point determined experimentally with this same proportional mix. Coordinates of point A are [24.85 (16.78 - 42.79) μM , 3.37 (2.28 - 5.81) μM] and those of point C [11.5 (9.13 - 13.83) μM , 1.56 (1.24 - 1.88) μM].120

Figure 6.3 (a) Percent maximal possible effect (MPE%) of L-NAME alone (A), ketamine alone (B) and the actual combination of ketamine and L-NAME in a fixed ratio proportion (0.8805 : 0.1195) in which the quantities of ketamine are in 0.5 fractions to its respective IC_{40} value (D) on the high intensity epsp. The horizontal dashed line represents the effect level 40% MPE. (b) Isobologram for the high intensity epsp at the effect level 40% MPE for the combinations ketamine and L-NAME in a fixed ratio proportion as indicated above. The dashed line is the line of additivity and

contains point A representing the calculated additivity quantities for this proportional combination. Point C is the combination point determined experimentally with this same proportional mix. Coordinates of point A are [18.63 (8.62 - 79.87) μM , 2.53 (1.17 - 10.84) μM] and those of point C [8.05 (5.03 - 10.91) μM , 1.09 (0.68 - 1.48) μM].....121

Figure 7.1 (a) Percent maximal possible effect (MPE%) of L-NAME alone (A), ketoprofen alone (B) and the actual combination of ketoprofen and L-NAME in a fixed ratio proportion (0.8805 : 0.1195) in which the quantities ketoprofen are in 0.5 fractions to its respective IC_{40} value (D) on the high intensity epsp. The horizontal dashed line represents the effect level 40% MPE. (b) Isobologram for the low intensity epsp at the effect level 40% MPE for the combinations ketoprofen and L-NAME in a fixed ratio proportion as indicated above. The dashed line is the line of additivity and contains point A representing the calculated additivity quantities for this proportional combination. Point C is the combination point determined experimentally with this same proportional mix. Coordinates of point A are [368.55 (326.72 - 414.85) μM , 50.02 (44.34 - 56.30) μM] and those of point C [163.65 (119.43 - 207.25) μM , 22.21 (16.21 - 28.13) μM].....131

Figure 7.2 (a) Percent maximal possible effect (MPE%) of L-NAME alone (A), ketoprofen alone (B) and the actual combination of ketoprofen and L-NAME in a fixed ratio proportion (0.8805 : 0.1195) in which the quantities ketoprofen are in 0.5 fractions to its respective IC_{40} value (D) on the low intensity epsp. The horizontal dashed line represents the effect level 40% MPE. (b) Isobologram for the low intensity epsp at the effect level 40% MPE for the combinations ketoprofen and L-NAME in a fixed ratio proportion as indicated above. The dashed line is the line of additivity and contains point A representing the calculated additivity quantities for this proportional combination. Point C is the combination point determined experimentally with this same proportional mix. Coordinates of point A are [528.64 (452.85 - 683.19) μM , 71.75 (61.46 - 92.72) μM] and those of point C [443.11 (355.36 - 569.28) μM , 60.14 (48.23 - 77.26) μM].....132

Figure 7.3 Percent maximal possible effect (MPE%) of L-NAME alone (A), ketoprofen alone (B) and the actual combination of ketoprofen and L-NAME in a fixed ratio proportion (0.8805 : 0.1195) in which the quantities of the constituents were the same as those used on the high intensity epsp. The horizontal dashed line represents the effect level 40% MPE.....132

Figure 8.1 Radiograph showing the correct placement of an intrathecal catheter at the

level of the fifth cervical vertebra in sheep.....	142
Figure 8.2 Intrathecal catheterisation of sheep.....	143
Figure 8.3 Mechanical nociceptive device used to stimulate a foreleg in sheep.....	144
Figure 8.4 Mechanical device calibration curve.....	145
Figure 8.5 Transverse sections of the cervical spinal cord of sheep 597 showing histopathological changes associated with penetration of the catheter into the spinal parenchyma.....	150
Figure 8.6 Transverse sections of the spinal cord and brain of sheep 46.....	151
Figure 8.7 (a) Time course showing the effect of intrathecal administration of xylazine (1.95 mM, 100 µl) and saline (0.9%, 100 µl) on mechanical nociceptive thresholds in sheep. The arrow represents the time treatments were given. (b-d) Xylazine induced hypoalgesia as assessed by the area under the curve (AUC) for 60 min (b) and 180 min post-treatment (c), but there was marked variation in individual AUC values (d). * Represents significant difference between xylazine and saline ($P < 0.0001$). Data are the mean \pm s.e.m. of 13 sheep.....	152
Figure 8.8 (a) Time course showing the effect of intrathecal administration of ketoprofen (200-3200 µM, 100 µl) and saline (0.9%, 100 µl) on mechanical nociceptive thresholds in sheep. The arrow represents the time treatments were given. (b-c) Ketoprofen had no significant effect on the area under the curve (AUC) for 60 min (b) and 180 min post-treatment (c) as compared to saline. (d-e) The concentration-effect curves for ketoprofen for 60 min (d) and 180 min post-treatment (e) were not significantly different to zero. Data are the mean \pm s.e.m. of 6 sheep.....	153
Figure 8.9 (a) Time course showing the effect of intrathecal administration of ketamine (25-400 µM, 100 µl) and saline (0.9%, 100 µl) on mechanical nociceptive thresholds in sheep. The arrow represents the time treatments were given. (b-c) Ketamine had no significant effect on the area under the curve (AUC) for 60 min (b) and 180 min post-treatment (c) as compared to saline. (d-e) The concentration-effect curves for ketamine for 60 min (d) and 180 min post-treatment (e) were not significantly different to zero. Data are the mean \pm s.e.m. of 6 sheep.....	154
Figure 8.10 (a) Time course showing the effect of intrathecal administration of	

ketoprofen : ketamine (0.955 : 0.045; 837.695-3350.78 μ M, 100 μ l) and saline (0.9%, 100 μ l) on mechanical nociceptive thresholds in sheep. The arrow represents the time treatments were given (a). (b-c) Ketoprofen : ketamine had no significant effect on the area under the curve (AUC) for 60 min (b) and 180 min post-treatment (c) as compared to saline. (d-e) The concentration-effect curves for ketoprofen : ketamine for 60 min (d) and 180 min post-treatment (e) were not significantly different to zero. * Represents significant difference between ketoprofen : ketamine concentrations ($P < 0.05$). Data are the mean \pm s.e.m. of 4 sheep.....155

Figure 8.11 (a) Time course showing the effect of intrathecal administration of NMDA (2 mM, 100 μ l) and saline (0.9%, 100 μ l) on mechanical nociceptive thresholds in sheep. The arrow represents the time treatments were given. (b) NMDA significantly reduced the area under the curve (AUC) for 30 min post-treatment as compared to saline. * Represents significant difference between NMDA and saline ($P < 0.0001$). Data are the mean \pm s.e.m. of 7 sheep.....156

Figure 8.12 (a) Time course showing the effect of intrathecal administration of saline (0.9%, 100 μ l), ketoprofen (3200 μ M, 100 μ l), ketamine (400 μ M, 100 μ l), and ketoprofen : ketamine (0.955 : 0.045; 3350.78 μ M, 100 μ l) followed by NMDA (2 mM, 100 μ l) on mechanical nociceptive thresholds in sheep. The arrow represents the time treatments were given before administering NMDA (time 0). (b) NMDA significantly reduced the area under the curve (AUC) for 30 min post-treatment as compared to saline, and this enhanced pain sensitivity was prevented by ketoprofen, ketamine, and a combination of both. * and † Represent significant differences between treatment and saline + NMDA ($P < 0.05$ and $P < 0.01$, respectively), ‡ represents significant difference between treatment and saline + saline ($P < 0.001$). Data are the mean \pm s.e.m. of 5 sheep; s.e.m. are not shown in (a) for clarity.....157

Abbreviations

8-pCPT-cGMP	8-para-chlorophenylthio cGMP, a membrane-permeable cGMP analogue
$[Ca^{2+}]_i$	intracellular calcium concentration
AA	arachidonic acid
AACOCF ₃	arachidonyl trifluoromethylketone, a type-unspecific PLA ₂ inhibitor
aCSF	artificial cerebrospinal fluid
AMPA	α -amino-3-hydroxy-5-methyl-4-isoxalone propionic acid
AUC	area under the curve
C5	fifth cervical vertebra
CaM	Ca ²⁺ -calmodulin complex
cAMP	3',5'-cyclic adenosine monophosphate
CB	cannabinoid
cGMP	3',5'-cyclic guanosine monophosphate
CGRP	calcitonin gen-related peptide
CI	confidence intervals
CNS	central nervous system
COX	cyclo-oxygenases
cPLA ₂	cytosolic Ca ²⁺ -dependent PLA ₂
CSF	cerebrospinal fluid
DAG	diacylglycerol
DRCAP	dorsal root compound action potential
DRG	dorsal root ganglion
DR-VRP	dorsal root evoked population ventral root potential
eNOS	endothelial NOS
epsp	excitatory postsynaptic potential
GABA	γ -aminobutyric acid
i.p.	intraperitoneal
i.t.	intrathecal
IC ₄₀	inhibitory concentration at 40% depression of maximum possible effect
IC ₅₀	inhibitory concentration at 50% depression of maximum effect, median inhibitory concentration
iNOS	inducible NOS
InsP ₃	inositol-(1,4,5) triphosphate
iPLA ₂	cytosolic Ca ²⁺ -independent PLA ₂

L-NAME	<i>N</i> ^o -nitro-L-arginine methyl ester
L-PGDS	lipocalin-type PGD synthase
MAFP	methyl arachydonyl fluorophosphanate, a type-unspecific PLA ₂ inhibitor
MPE	maximum possible effect
mPGS1	microsomal PGE synthase 1
mPGS2	microsomal PGE synthase 2
MSR	monosynaptic compound action potential
N	Newtons
NF-κB	nuclear factor-κB
NK ₁	neurokinin ₁ receptor
NMDA	<i>N</i> -methyl-D-aspartate
nNOS	neuronal NOS
NO	nitric oxide
NOS	nitric oxide synthase
NSAIDs	non-steroidal anti-inflammatory drugs
ODQ	1 <i>H</i> -[1,2,4]oxadiazolo[4,3- α]quinoxalin-1-one, a gyanylate cyclase blocker
PCOX-1a	partial COX-1a
PCOX-1b	PCOX-1a
PGDS	PGD synthases
PGES	PGE synthase
PGFS	PGF synthase
PGs	prostaglandins
PKA	protein kinase A
PKC	protein kinase C
PKG	cGMP-dependent protein kinases
PLA ₂	phospholipase A ₂
PS	phosphatidylserine
PSD-93	postsynaptic density-93
PSD-95	postsynaptic density-95
Rp-8-p-CPT-cGMPS	Rp-8-p[(4-Chlorophenyl)thiol]-cGMPS triethylamine, a selective PKG-I α inhibitor
SP	substance P
sPLA ₂	secretory PLA ₂